Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 11/20 | 0.59 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.59 |
| ▸ | APP | P05067 | 1/20 | 0.56 |
| ▸ | CYP1A1 | P04798 | 4/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.52 |
| ▸ | CYP1B1 | Q16678 | 4/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5570074 | 0.88 | CYP1A1 (0.55) | ABCG2ADORA2AAPPCYP1A1CYP1A2 | |
| SCHEMBL15170212 | 0.84 | ADORA2A (0.52) | ABCG2ADORA2AAPPCYP1A2ADORA1 | |
| SCHEMBL16038291 | 0.81 | ABCG2 (0.55) | ABCG2 | |
| SCHEMBL20426104 | 0.80 | ABCG2 (0.55) | ABCG2ADORA2ACYP1A2ADORA1 | |
| SCHEMBL29593101 | 0.79 | CYP1A1 (0.77) | ABCG2ADORA2ACYP1A1CYP1A2CYP1B1 | |
| SCHEMBL1395347 | 0.79 | CYP1A1 (0.77) | ABCG2ADORA2ACYP1A1CYP1A2CYP1B1 | |
| SCHEMBL27915424 | 0.78 | ADORA2A (0.58) | ABCG2ADORA2AAPPADORA1 | |
| Hydrochloric Acid SCHEMBL29281621 | 0.78 | CYP1A1 (0.77) | ABCG2ADORA2ACYP1A1CYP1A2CYP1B1 | |
| SCHEMBL31061566 | 0.78 | CYP1A1 (0.68) | ABCG2ADORA2AAPPCYP1A1CYP1A2 | |
| SCHEMBL30301811 | 0.78 | NR1I3 (0.63) | ABCG2APPCYP1A1CYP1A2CYP1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8440674-B2 | Substituted pyrimidine compounds as RAF inhibitors and methods of use | AMGEN INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-20070185324-A1 | Nitrogen-containing bicyclic heteroaryl compounds and methods of use | AMGEN INC. | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185324-A1 | Nitrogen-containing bicyclic heteroaryl compounds and methods of use | BRAF, NRAS, RAF1 | ABCG2 905/4885ADORA2A 307/4885APP 4268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.